Ex­elix­is, Bris­tol-My­ers mount piv­otal study of Cabo/Op­di­vo com­bo for front­line kid­ney can­cer

Just days af­ter re­view­ing a promis­ing start com­bin­ing Bris­tol-My­ers Squibb’s check­point in­hibitor Op­di­vo (nivolum­ab) with Cabome­tyx (cabozan­ti­nib), Ex­elix­is is rolling out a late-stage part­ner­ship that will take the com­bo in­to a piv­otal Phase III study as a front­line ther­a­py for kid­ney can­cer. And not sat­is­fied with the one check­point tie-up, the South San Fran­cis­co-based biotech al­so an­nounced a deal this morn­ing to col­lab­o­rate with Roche on a com­bi­na­tion of its drug Tecen­triq (ate­zolizum­ab) and cabo.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER